Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its investigational obesity drug, VK2735, as the biotech positions itself to ...

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing risks remain. Click to know why VKTX is a Buy.

Also Read: Viking Therapeutics Stock Surges As Company Advances Weight Loss Drug To Late-Stage Trial: What Investors Need To Know. Results showed VK0214 to be safe and well-tolerated following ...

Shares of Viking Therapeutics (VKTX) are up 13% to $25.17 in early trading while Structure Therapeutics (GPCR) is up 7% to 17.02.Stay Ahead of ...

Viking Therapeutics Inc.’s stock soared 8% ... to support the commercialization of its oral obesity drug VK2735. The deal covers supply of both the active pharmaceutical ingredient, or API ...

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the ...

Viking Therapeutics (NASDAQ: VKTX) is operating in one of the highest-growth pharma areas around. I'm talking about the weight loss drug market -- one that Morgan Stanley analysts say may multiply ...